Geoffrey Ginsburg

Overview:

Dr. Geoffrey S. Ginsburg's research interests are in the development of novel paradigms for developing and translating genomic information into medical practice and the integration of personalized medicine into health care.

Positions:

Professor of Medicine

Medicine, Cardiology
School of Medicine

Director of Duke Center for Applied Genomics and Precision Medicine

Duke Center for Applied Genomics and Precision Medicine
School of Medicine

Professor in Pathology

Pathology
School of Medicine

Professor in the School of Nursing

School of Nursing
School of Nursing

Member of the Duke Cancer Institute

Duke Cancer Institute
School of Medicine

Education:

M.D. 1984

Boston University

Ph.D. 1984

Boston University

Medical Resident, Medicine

Beth Israel Deaconess Medical Center

Fellow in Cardiology, Medicine

Beth Israel Deaconess Medical Center

Research Fellow in Cardiology, Medicine

Children's Hospital Boston

Grants:

Building and Deploying a Genomic-Medicine Risk Assessment Model for Diverse Primary Care Populations.

Administered By
Duke Center for Applied Genomics and Precision Medicine
Awarded By
National Institutes of Health
Role
Investigator
Start Date
End Date

The IGNITE II CC: Engagement, Coordination, Demonstration, and Dissemination

Administered By
Duke Center for Applied Genomics and Precision Medicine
Awarded By
National Institutes of Health
Role
Principal Investigator
Start Date
End Date

The IGNITE II CC: Engagement, Coordination, Demonstration, and Dissemination

Administered By
Duke Center for Applied Genomics and Precision Medicine
Awarded By
National Institutes of Health
Role
Principal Investigator
Start Date
End Date

The Role of Junctophilin Type 2 in Cardiac Node Automaticity

Administered By
Pediatrics, Cardiology
Awarded By
National Institutes of Health
Role
Mentor
Start Date
End Date

Predicting prebiotic effects on human microbiota, behavior, and cognition.

Administered By
Molecular Genetics and Microbiology
Awarded By
Office of Naval Research
Role
Collaborator
Start Date
End Date

Publications:

Correction: Opportunities to implement a sustainable genomic medicine program: lessons learned from the IGNITE Network.

An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Authors
Levy, KD; Blake, K; Fletcher-Hoppe, C; Franciosi, J; Goto, D; Hicks, JK; Holmes, AM; Kanuri, SH; Madden, EB; Musty, MD; Orlando, L; Pratt, VM; Ramos, M; Wu, R; Ginsburg, GS
MLA Citation
Levy, Kenneth D., et al. “Correction: Opportunities to implement a sustainable genomic medicine program: lessons learned from the IGNITE Network.Genet Med, July 2020. Pubmed, doi:10.1038/s41436-020-0911-5.
URI
https://scholars.duke.edu/individual/pub1453218
PMID
32719393
Source
pubmed
Published In
Genet Med
Published Date
DOI
10.1038/s41436-020-0911-5

Influence of Sex on Platelet Reactivity in Response to Aspirin.

Background There are sex differences in the efficacy and safety of aspirin for the prevention of myocardial infarction and stroke. Whether this is explained by underlying differences in platelet reactivity and aspirin response remains poorly understood. Methods and Results Healthy volunteers (n=378 208 women) and patients with coronary artery disease or coronary artery disease risk factors (n=217 112 women) took aspirin for 4 weeks. Light transmittance aggregometry using platelet-rich plasma was used to measure platelet reactivity in response to epinephrine, collagen, and ADP at baseline, 3 hours after the first aspirin dose, and after 4 weeks of daily aspirin therapy. A subset of patients underwent pharmacokinetic and pharmacodynamic assessment with levels of salicylate and cyclooxygenase-1-derived prostaglandin metabolites and light transmittance aggregometry in response to arachidonic acid and after ex vivo exposure to aspirin. At baseline, women had increased platelet aggregation in response to ADP and collagen. Innate platelet response to aspirin, assessed with ex vivo aspirin exposure of baseline platelets, did not differ by sex. Three hours after the first oral aspirin dose, platelet aggregation was inhibited in women to a greater degree in response to epinephrine and to a lesser degree with collagen. After 4 weeks of daily therapy, despite higher salicylate concentrations and greater cyclooxygenase-1 inhibition, women exhibited an attenuation of platelet inhibition in response to epinephrine and ADP. Conclusions We observed agonist-dependent sex differences in platelet responses to aspirin. Despite higher cyclooxygenase-1 inhibition, daily aspirin exposure resulted in a paradoxical attenuation of platelet inhibition in response to epinephrine and ADP over time in women but not in men.
Authors
Friede, KA; Infeld, MM; Tan, RS; Knickerbocker, HJ; Myers, RA; Dubois, LG; Thompson, JW; Kaddurah-Daouk, R; Ginsburg, GS; Ortel, TL; Voora, D
MLA Citation
Friede, Kevin A., et al. “Influence of Sex on Platelet Reactivity in Response to Aspirin.J Am Heart Assoc, vol. 9, no. 14, July 2020, p. e014726. Pubmed, doi:10.1161/JAHA.119.014726.
URI
https://scholars.duke.edu/individual/pub1452145
PMID
32654613
Source
pubmed
Published In
Journal of the American Heart Association
Volume
9
Published Date
Start Page
e014726
DOI
10.1161/JAHA.119.014726

The Project Baseline Health Study: a step towards a broader mission to map human health.

The Project Baseline Health Study (PBHS) was launched to map human health through a comprehensive understanding of both the health of an individual and how it relates to the broader population. The study will contribute to the creation of a biomedical information system that accounts for the highly complex interplay of biological, behavioral, environmental, and social systems. The PBHS is a prospective, multicenter, longitudinal cohort study that aims to enroll thousands of participants with diverse backgrounds who are representative of the entire health spectrum. Enrolled participants will be evaluated serially using clinical, molecular, imaging, sensor, self-reported, behavioral, psychological, environmental, and other health-related measurements. An initial deeply phenotyped cohort will inform the development of a large, expanded virtual cohort. The PBHS will contribute to precision health and medicine by integrating state of the art testing, longitudinal monitoring and participant engagement, and by contributing to the development of an improved platform for data sharing and analysis.
Authors
Arges, K; Assimes, T; Bajaj, V; Balu, S; Bashir, MR; Beskow, L; Blanco, R; Califf, R; Campbell, P; Carin, L; Christian, V; Cousins, S; Das, M; Dockery, M; Douglas, PS; Dunham, A; Eckstrand, J; Fleischmann, D; Ford, E; Fraulo, E; French, J; Gambhir, SS; Ginsburg, GS; Green, RC; Haddad, F; Hernandez, A; Hernandez, J; Huang, ES; Jaffe, G; King, D; Koweek, LH; Langlotz, C; Liao, YJ; Mahaffey, KW; Marcom, K; Marks, WJ; Maron, D; McCabe, R; McCall, S; McCue, R; Mega, J; Miller, D; Muhlbaier, LH; Munshi, R; Newby, LK; Pak-Harvey, E; Patrick-Lake, B; Pencina, M; Peterson, ED; Rodriguez, F; Shore, S; Shah, S; Shipes, S; Sledge, G; Spielman, S; Spitler, R; Schaack, T; Swamy, G; Willemink, MJ; Wong, CA
MLA Citation
Arges, Kristine, et al. “The Project Baseline Health Study: a step towards a broader mission to map human health.Npj Digit Med, vol. 3, 2020, p. 84. Pubmed, doi:10.1038/s41746-020-0290-y.
URI
https://scholars.duke.edu/individual/pub1448045
PMID
32550652
Source
pubmed
Published In
Npj Digital Medicine
Volume
3
Published Date
Start Page
84
DOI
10.1038/s41746-020-0290-y

Lipoprotein subclasses associated with high-risk coronary atherosclerotic plaque: insights from the PROMISE clinical trial

Authors
McGarrah, RW; Ferencik, M; Giamberardino, SN; Coles, A; Hoffmann, U; Ginsburg, GS; Kraus, WE; Douglas, PS; Shah, SH
MLA Citation
McGarrah, R. W., et al. “Lipoprotein subclasses associated with high-risk coronary atherosclerotic plaque: insights from the PROMISE clinical trial.” European Heart Journal, vol. 40, OXFORD UNIV PRESS, 2019, pp. 51–51.
URI
https://scholars.duke.edu/individual/pub1431515
Source
wos
Published In
European Heart Journal
Volume
40
Published Date
Start Page
51
End Page
51

Overview: Genomic and precision medicine for infectious and inflammatory disease

© 2019 Elsevier Inc. All rights reserved. A century of advances in infectious disease diagnosis, treatment, and prevention changed the face of medicine and global health. However, challenges persist including high mortality from sepsis, emerging antimicrobial resistance, and globalization that increases pandemic risks. More recently, similar achievements are being made in the field of autoimmune and inflammatory diseases, but gains are slowed by difficulties with non-specific, clinical diagnoses. These challenges can be mitigated through implementation of the tools of precision medicine. This volume covers a broad range of topics where use of these tools holds promise for an exciting era of rapid progress.
Authors
Woods, CW; Tsalik, EL
MLA Citation
Woods, C. W., and E. L. Tsalik. “Overview: Genomic and precision medicine for infectious and inflammatory disease.” Genomic and Precision Medicine: Infectious and Inflammatory Disease, 2019, pp. 1–7. Scopus, doi:10.1016/B978-0-12-801496-7.00001-0.
URI
https://scholars.duke.edu/individual/pub1434991
Source
scopus
Published Date
Start Page
1
End Page
7
DOI
10.1016/B978-0-12-801496-7.00001-0

Research Areas:

Antigens
Biological Assay
Biosensing Techniques
Cytoskeletal Proteins
Immune System
Membrane Proteins
Nucleic Acid Hybridization
Pneumonia, Viral